Compare · LIVN vs VRAY
LIVN vs VRAY
Side-by-side comparison of LivaNova PLC (LIVN) and ViewRay Inc. (VRAY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LIVN and VRAY operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $3.97B, about 5.5x VRAY ($726.7M).
- LIVN has hit the wire 5 times in the past 4 weeks while VRAY has been quiet.
- LIVN has more recent analyst coverage (20 ratings vs 9 for VRAY).
- Company
- LivaNova PLC
- ViewRay Inc.
- Price
- $74.75+3.36%
- $0.03-39.95%
- Market cap
- $3.97B
- $726.7M
- 1M return
- +5.45%
- -
- 1Y return
- +61.30%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 5
- 0
- Recent ratings
- 20
- 9
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
ViewRay Inc.
ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, Taiwan, the United Kingdom, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
Latest LIVN
- LivaNova Appoints Anne Liddy as Chief Legal Officer
- SEC Form SD filed by LivaNova PLC
- Director Bianchi Francesco sold $136,350 worth of Ordinary Shares (1,800 units at $75.75), decreasing direct ownership by 20% to 7,228 units (SEC Form 4)
- LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
- LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
- SEC Form IRANNOTICE filed by LivaNova PLC
- SEC Form 10-Q filed by LivaNova PLC
- LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
- Amendment: SEC Form SCHEDULE 13G/A filed by LivaNova PLC
Latest VRAY
- SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)
- SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)
- SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)
- NUBURU Appoints Brian Knaley as new CEO
- SEC Form 25-NSE filed by ViewRay Inc.
- ViewRay Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form NT 10-Q filed by ViewRay Inc.
- SEC Form SC 13G/A filed by ViewRay Inc. (Amendment)
- SEC Form 4 filed by Shah Sanket
- SEC Form 4 filed by Podbelski Adam Andrew